Most human cells lack sufficient telomerase to maintain telomeres, hence these genetic elements shorten with time and stress, contributing to aging and disease. In January 2007 a commercial health maintenance program, PattonProtocol-1, was launched which included a natural product-derived telomerase activator (TA-65 ® , 10-50 mg daily), a comprehensive dietary supplement pack, and physician counseling/laboratory tests at baseline and every 3-6 months thereafter. We report here analysis of the first year of data focusing on the immune system. Low nanomolar levels of TA-65® moderately activated telomerase in human keratinocytes, fibroblasts, and immune cells in culture; similar plasma levels of TA-65® were achieved in pilot human pharmacokinetic studies with single 10-50 mg doses. The most striking in vivo effects were declines in the percent senescent cytotoxic (CD8 + /CD28 -) T cells (1.5, 4.4, 8.6, and 7.5% at 3, 6, 9, 12 months, respectively; p=NS, 0.018, 0.0024, 0.0062) and natural killer cells at 6 and 12 months (p=0.028 and 0.00013, respectively). Most of these decreases were seen in CMV seropositive subjects. In a subset of subjects, the distribution of telomere lengths in leukocytes at baseline and 12 months were measured. Although mean telomere length did not increase, there was a significant reduction in the percent short (<4 kbp) telomeres (p=0.037). No adverse events were attributed to PattonProtocol-1. We conclude that the protocol lengthens critically short telomeres and remodels the relative proportions of circulating leukocytes of CMV + subjects toward the more "youthful" profile of CMVsubjects. Controlled randomized trials are planned to assess TA-65 ® -specific effects in humans. is one of the inventors of TA-65. He consults for TA Sciences and is personally taking TA-65. He owns stock and stock options in Geron Corporation, a company that is developing telomerase activators for therapeutic purposes and the company that licensed TA-65 to TA Sciences. He is co-founder, President and CEO, and holds stock in Telome Health, Inc., a diagnostics company that will provide telomere-and telomerase-related assay services to the healthcare industry.
People take dietary supplements with the intent to preserve mental, physical, and emotional health and vigor into old age. Although drugs and surgical procedures that target diseases of the elderly will hopefully arrest or partially reverse tissue damage caused by aging and chronic stress, measures to maintain health are arguably a better approach to lengthening our healthy lifespan. Most dietary supplement programs include combinations of vitamins, antioxidants, and other constituents, some of which have been shown to have significant health benefits in controlled clinical studies, while others may show adverse effects [1] [2] [3] [4] [5] [6] , underscoring the need to assess functional effects of combination products. This paper presents initial data from an ongoing observational study of a novel dietary supplement program, PattonProtocol-1, which includes a natural product-derived telomerase activator targeting a fundamental aspect of cellular aging.
Telomerase is an enzyme that synthesizes the specific DNA sequence at telomeres, i.e. the terminal DNA at the ends of all chromosomes [7] [8] . Telomeres are essential genetic elements responsible for protecting chromosome ends from being recognized as "broken DNA." Since telomeric DNA cannot be fully replicated by conventional DNA polymerases, and since telomeres undergo degradative processing and are a "hotspot" for oxidative damage 9 , telomeres will gradually shorten with time and cell division unless there is sufficient telomerase activity to maintain telomere length.
Telomerase is activated in fetal development, thus protecting telomeres from significant loss during this period of dramatic cell expansion. [10] [11] However, telomerase is repressed before birth in most somatic tissue, and as a consequence, birth marks the beginning of telomere erosion in most tissues throughout life. Tissues with continual cell turnover or periods of rapid proliferation are "telomerase competent" in that they up-regulate telomerase during early phases F o r P e e r R e v i e w $ASQ8057093_File000024_133971815.doc of progenitor expansion. [12] [13] All adult somatic stem cells appear to be capable of activating telomerase during tissue regeneration. However, these periods of activation are insufficient to prevent telomere loss, and this is compounded by a decreased ability to activate telomerase during aging and stress. [14] [15] [16] In addition, stress can accelerate telomere loss by increasing cell turnover and the amount of telomeric DNA lost per cell division. [17] [18] In cross-sectional studies humans lose telomeric DNA at a very modest rate of about 15-60 bp per year, likely reflecting the small numbers of stem cells that are actively dividing in proliferative tissues compared to the total stem cell reserve, and the quiescent state of cells in other tissues. Telomere shortening has been investigated in human cells in culture, in human genetic diseases with mutated telomerase, and in animal models of telomerase deficiency. 13, [19] [20] [21] [22] [23] [24] [25] [26] These studies point to a causal relationship between telomere loss, cell aging, reduced tissue regeneration, and loss of tissue structure and function. In support of this causal relationship, epidemiological studies show that short telomeres in humans are a risk factor for atherosclerosis, hypertension, cardiovascular disease, Alzheimer's, infections, diabetes, fibrosis, metabolic syndrome, cancer, and overall mortality. 18, [24] [25] [27] [28] [29] [30] Chronic viral infections such as CMV and HIV accelerate telomere loss and premature aging of the immune system, especially the viral-specific cytotoxic T cells [31] [32] [33] [34] [35] [36] responsible for killing infected cells. In addition to telomere loss, these cells often lack expression of the costimulatory receptor, CD28, have reduced proliferative capacity, reduced ability to secrete antiviral cytokines and chemokines, increased resistance to apoptosis, and compromised ability to lyse infected cells. About 50% of the US population is infected with CMV as judged by circulating CMV-specific antibodies, but after an initial 30% seropositivity rate by age ≈10, there is ≈1% annual seroconversion rate throughout life leading to ≈90% seropositivity by the ninth 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 decade. This linear increase has made it difficult to distinguish the effects of pure immunosenescence from those that can be attributed to this extremely common virus. [37] [38] Here we report initial findings from a dietary supplement program which includes TA-65 ® , a purified small molecule telomerase activator derived from an extract of a plant commonly used in traditional Chinese medicine. Telomerase activation and functional studies on a related molecule (TAT2) from the same plant have been previously reported for human skin keratinocytes and immune cells in culture. 36 Effects of TAT2 in tissue culture studies with CD8 + T cells from HIV/AIDS subjects included increased replicative capacity, improved cytokine and chemokine responses to antigens, and increased killing of autologous HIV-infected CD4 + cells.
Methods

PattonProtocol-1
PattonProtocol-1 was launched in January 2007 by TA Sciences (New York) as a commercial age-management product composed of a natural product-derived telomerase activator (TA-65 ® , described below), a dietary supplement pack (online material S1), laboratory testing ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56 
Results
Mechanism of Action
TA-65 ® activates telomerase in human neo-natal keratinocytes and fetal fibroblasts in culture TA-65 ® up-regulates telomerase activity in low and mid-passage human neo-natal keratinocytes 2-3 fold in a dose-responsive manner (Fig. 1A) . In these studies, activation was 2-3
fold at the lowest concentrations tested (30-100 nM) and activation was not as great at higher concentrations. This pattern is similar to that seen for TAT2, a related molecule tested in human 
Baseline Observations
The relationships between age and various biomarkers including telomere length have been reported in a number of cross-sectional studies. Table 2 shows mean values, standard deviations, count, slope and R 2 from linear regression on subject age, and the statistical significance of the slope for the baseline tests investigated in this report. As expected, this population showed a highly significant decline as a function of client age in both lymphocyte and granulocyte telomere length by FlowFISH analysis, and the slopes of the decline (55 and 34 bp/year; p=10 -15 and 10 -8 , respectively) are comparable to those reported previously. [43] [44] [45] Agedependent increases are seen in the percent senescent (CD8 + CD28 -) cytotoxic T cells, percent NK cells, percent and absolute number of neutrophils. Significant age-dependent decreases are seen in naïve (CD8 + CD95 -) cytotoxic T cells, B-cells, and lymphocytes.
Since CMV infection can have a significant impact on immune markers 37,46 , we analyzed the age-dependency of baseline immune subsets by CMV status (Fig. 2 and Table 3 ). Lymphocyte, but not granulocyte, telomere length was longer in CMVsubjects than that in CMV + subjects, suggesting that CMV infection drives increased turnover (and hence telomere shortening) in lymphocytes, but has relatively little effect on hematopoietic stem cells. Telomere length in granulocytes is considered a surrogate of telomere length in hematopoietic stem cells due to their short transit time to peripheral blood, and short half-life in circulation [42] . The ages of the CMV + and CMVsubjects (65±12 and 62±13, respectively) were not significantly different, but the mean lymphocyte TL in CMV + individuals was 680 bp less than that observed in the CMVgroup (p=0.003), suggesting an acceleration of aging by about 10 years in the CMV + group based on -55bp/y for lymphocytes.
As expected, baseline numbers and the rate of increase in senescent cytotoxic T cells (CD8 + /CD28 -) in percent and absolute counts was highest in the CMV + population ( Table 3 and Fig. 2 C,D) . The slight increase in % senescent cytotoxic T cells as a function of age in CMVsubjects ( Fig. 2C ) despite declining absolute numbers of these cells (Fig. 2D) is a consequence of a significant decline in total CD8 + cells as a function of donor age in CMVsubjects ( Fig. 2 E,F). The difference in the mean number of CD8 + T cells between CMV + and CMVsubjects (208 cells/µL) is essentially accounted for by the difference in mean number of senescent CD8 + T cells between these two subpopulations (200 cells/µL) ( Table 3) . Although the %CD8 + CD28 + cells at baseline was significantly higher in CMVsubjects (p<0.0001), this was due primarily to the elevated absolute number of CD8 + CD28cells in the CMV + subset (i.e. an increased denominator for the CMV + group). The absolute number of non-senescent cytotoxic T cells (CD8 + CD28 + ) was not significantly different between CMV + and CMVsubjects ( Table 3) .
CMV + subjects had significantly fewer absolute and percent naïve cytotoxic T cells (CD8 + CD95 -) at baseline than did CMVsubjects (p<0.0005 and 0.07, respectively) ( Table 3) , 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w $ASQ8057093_File000024_133971815.doc but in both populations there was dramatic reduction in the absolute and relative abundance of these cells as a function of subject age ( Fig. 2 G,H) , consistent with previous studies. [47] [48] In 80-90 year old subjects there were <50 naïve CD8 + cells/µL.
A novel finding in the baseline dataset is an apparent effect of CMV infection on neutrophils: CMVsubjects show an increase in neutrophil number and percentage as a function of subject age compared to an essentially flat profile with age for the CMV + subjects ( Fig. 2 I,   J ). At baseline, the mean number of neutrophils in CMVsubjects was about 20% higher than that in CMV + subjects (p=0.02 by absolute counts, p=0.003 by %) ( Table 3 ). There was also highly significant increase in baseline percent (p=0.00015) and absolute numbers of NK cells (p=0.006) in the total population ( Table 2) , but there was no significant difference between CMVand CMV + subjects.
Changes from Baseline
Reduction in Percent Cells with Short Telomeres
Two independent measures of median or mean telomere length (by FlowFISH and qPCR) showed no consistent change with time on PattonProtocol-1 (data not shown). However, we also analyzed the distribution of individual telomere lengths using automated high-throughput confocal microscopy (HT-qFISH 42 ). Telomere signals within the nuclei of white blood cells were analyzed from 13 subjects at baseline and a follow-up time-point between 12 or 18 months.
Mean telomere length by HTqFISH correlates relatively well with median telomere length by
FlowFISH (supplemental data S2) and also showed no consistent change of overall telomere length ( Fig. 3A) . However, HTqFISH revealed a decline in the percentage of nuclei with short 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 . 3B) . Given these data, we used a 1-tailed paired t-test to determine the probability that the overall mean reduction across all 13 subjects was due to chance (p=0.038). In separate studies in murine cells in culture and in vivo we have shown that TA-65® alone will reduce the percentage of cells with short telomeres with minimal effects on mean telomere length (MB, manuscript in preparation).
Positive Remodeling of the Immune System
There were a number of striking changes from baseline in the adaptive and innate immune system of subjects on PattonProtocol-1. We saw statistically significant "age-reversal" effects in the number and percent of senescent (CD8 + CD28) cytotoxic T cells, particularly after 3 months ( Fig. 4A) . Senescent CD8 + CD28 T cells dropped with a linear trend from roughly 39% in the baseline population to about 36% at 12 months in the overall population (p=0.0068 at 12M). Most of this effect was due to a 20% drop in the number of CD8 + CD28 cells in the CMV + population ( Fig. 4D, p=0 .0044 at 12M). This decrease, relative to the age-related increase of 0.57%/year and 3 CD28 cells/year in CMV + individuals, represent an apparent age reversal of ≈5-20 years in this biomarker of immune aging.
At baseline, CMV + individuals had a significantly lower number and percent of neutrophils compared to CMV individuals ( Table 3) . After 3 months on PattonProtocol-1, there was an overall increase in number and percent of neutrophils ( Fig. 4B ) which was primarily driven by the effects of the Protocol in the CMV + subjects ( Fig. 4D ), suggesting that as in the 
Discussion and Conclusions
The inability to maintain telomeres with age and chronic stress has been linked to declining health and the increased risk of disease and death from many causes, including cancer 16, 25, [49] [50] [51] [52] . In this study, we report that a one-year health maintenance program consisting of a dietary supplement pack combined with a natural-product derived telomerase activator results in a decreased percentage of short leukocyte telomeres and remodeling of the relative proportions of the circulating leukocytes of CMV + subjects toward the more "youthful" profile of CMVsubjects.
One of the strengths of our study is the low CMV-positivity rate (54%) in a relatively older population, which allows us to separate the effects of age and CMV status on immunosenescence. It also serves to mitigate one of our study's weaknesses-the lack of a control group-as the subjects were initially unaware of their CMV status and their subsequent knowledge is unlikely to have caused the segregation of many of the effects of the protocol by CMV status. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Age-related changes in the innate immune system have not been as well characterized as those of the adaptive immune system, although the importance of changes in the former is increasingly being recognized 55 . It is generally agreed that the per-cell activity of neutrophils as measured by oxidative burst, phagocytosis, and chemotaxis decreases with age. 56 There is less agreement on the effect of aging on neutrophil number which has been variously reported to be preserved 57 , decreased 58 , or increased 53 with age. CMV status is not reported in the first two studies, but in the last study from the above-mentioned NONA cohort, the increase in neutrophil number is based on a comparison between 18 middle-aged (55 y.o.) subjects with a 55% CMV + 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 year interval in the very old group. This suggests that there is selection for those very old subjects able to increase their circulating neutrophils in the face of deteriorating tissues, increased inflammation, and increased exposure to infectious agents. Our novel finding that by age 62 the neutrophil number is 20% higher and continues to increase with age only in CMVsubjects can be interpreted as a compensatory increase in the face of declining per cell activity and barrier function, as well as increased antigenic load. The absence of a cross-sectional increase with age in neutrophil number in CMV + subjects suggests that this compensation is blocked in the CMV + subjects perhaps due to inhibitory cytokine production by the senescent T cells. The effect of the protocol to increase neutrophil count in CMV + subjects can be interpreted as a salutary removal of this block in part through reduction in the number of senescent T cells.
There is a broad consensus that NK cell number increases with age to compensate for decreased per cell activity which results from impaired signal transduction 59 , but other mechanisms such as decreased barrier function and increased antigenic/pathogenic load may also contribute to increased NK cells with age 60 . The decrease in NK cell number induced by the protocol is an "age reversal" but as we did not measure NK activity we cannot say whether it is from improved barrier function or improved signal transduction. Unlike other cells of the innate immune system, NK cells proliferate after activation and experience further telomere shortening once they are released from the bone marrow 61 . The decrease in the percentage of short telomeres we found could result in improved signal transduction as a mechanism for the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Physicians who monitored the health of the current study subjects through one year on the product reported no adverse events that were likely related to the protocol. However, two subjects who recently escalated their daily dose reported feeling "anxious" on 100 mg/day but not when they switched back to 50 mg/day. A placebo-controlled study will be needed to determine if this potential adverse effect is real. No new cases of cancer or cardiovascular disease were reported during the overall 260 person-years of dosing with PattonProtocol-1 through June 2010, and this is statistically significant (p<0.05, cancer; p<0.02, CVD) assuming baseline age-specific risks in our population were similar to those of the US population.
TA-65 ® activated telomerase in cultured human cells at concentrations seen in the plasma of subjects on the protocol. Paradoxically, although ≈40% of subjects showed an increase in mean telomere length over time, on average across all subjects there was a non-significant decline in mean telomere length. However, we speculate this effect is explained by cell dynamics and the fact that telomerase preferentially lengths the shortest telomeres [62] [63] [64] . Rescue and selective expansion of near-senescent cells with short telomeres could lead to a reduction in the population mean telomere length despite some lengthening of telomeres in all cells. Since detrimental effects of telomere loss are primarily driven by short, dysfunctional telomeres, and loss of tissue function and disease onset in proliferative tissues have been associated with telomere lengths <4 kbp 25,65 , we believe that our observed reduction in telomeres <4 kbp in subjects on PattonProtocol-1 is a significant, positive response, and that TA-65® contributes to the apparent benefit of the dietary supplement. In support of this, studies with TA-65® given 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Sciences; he consults for TA Science, is a client of TA Sciences that is taking TA-65, and is one of the subjects studied to generate data for this manuscript. He is the founder, President and CEO of Sierra Sciences, a company that develops therapeutics for inducing telomerase expression and has provided financial support for some of the studies described in this manuscript.
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